Xeris Biopharma Holdings Inc. Stock
We can see a decrease in the price for Xeris Biopharma Holdings Inc.. Compared to yesterday it has lost -€0.046 (-2.660%).
Currently there is a rather positive sentiment for Xeris Biopharma Holdings Inc. with 4 Buy predictions and 0 Sell predictions.
Based on the current price of 1.75 € the target price of 4 € shows a potential of 128.31% for Xeris Biopharma Holdings Inc. which would more than double the current price.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | -2.660% | 7.419% | -7.203% | -19.633% | -18.889% | -41.444% | - |
| Ardelyx Inc. | 28.120% | 34.723% | 16.633% | 93.717% | 39.758% | 44.250% | - |
| Evolus Inc | 4.240% | 17.143% | 2.500% | 61.842% | 35.912% | 68.493% | - |
| Salarius Pharmaceuticals Inc. | -1.300% | 6.573% | 5.581% | -68.472% | -18.198% | -98.220% | -99.993% |
Comments
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $5.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target lowered by analysts at Piper Sandler from $5.00 to $4.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $4.50 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat